Biotech Values

[DewDiligence]

Reposted from the GTCB board on iHub (msg #65):

>DEW, could you explain the significance in the difference in rhAT and pAT from the article you posted. I gathered that the pAT stayed active longer in the bloodstream than the rhAT. Please also explain how this could impact approval and prescribing choice by MD's<

For those who haven’t seen the reference, here’s it is: #msg-11801772.

ATryn evidently does have a shorter half-life than plasma-derived antithrombin due to a different proportion of the two AT isoforms. When I asked GTC about this, the answer was that the shorter half-life is immaterial in most clinical settings. They felt that, if anything, the shorter half-life is a modest benefit in that it makes it easier to avert an overdose.